- Home
- PBHC vs CLYM Comparison
PBHC vs CLYM Comparison
Compare PBHC & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBHC
- CLYM
- Stock Information
- Founded
- PBHC 1859
- CLYM 2018
- Country
- PBHC United States
- CLYM United States
- Employees
- PBHC N/A
- CLYM N/A
- Industry
- PBHC Major Banks
- CLYM
- Sector
- PBHC Finance
- CLYM
- Exchange
- PBHC Nasdaq
- CLYM NYSE
- Market Cap
- PBHC 108.9M
- CLYM 101.6M
- IPO Year
- PBHC N/A
- CLYM 2021
- Fundamental
- Price
- PBHC $17.24
- CLYM $1.47
- Analyst Decision
- PBHC
- CLYM
- Analyst Count
- PBHC 0
- CLYM 0
- Target Price
- PBHC N/A
- CLYM N/A
- AVG Volume (30 Days)
- PBHC 6.2K
- CLYM 331.6K
- Earning Date
- PBHC 01-31-2025
- CLYM 03-27-2025
- Dividend Yield
- PBHC 2.32%
- CLYM N/A
- EPS Growth
- PBHC N/A
- CLYM N/A
- EPS
- PBHC 0.62
- CLYM N/A
- Revenue
- PBHC $40,020,000.00
- CLYM N/A
- Revenue This Year
- PBHC N/A
- CLYM N/A
- Revenue Next Year
- PBHC N/A
- CLYM N/A
- P/E Ratio
- PBHC $27.94
- CLYM N/A
- Revenue Growth
- PBHC N/A
- CLYM N/A
- 52 Week Low
- PBHC $11.41
- CLYM $1.41
- 52 Week High
- PBHC $19.86
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- PBHC 55.65
- CLYM N/A
- Support Level
- PBHC $17.00
- CLYM N/A
- Resistance Level
- PBHC $17.26
- CLYM N/A
- Average True Range (ATR)
- PBHC 0.20
- CLYM 0.00
- MACD
- PBHC 0.03
- CLYM 0.00
- Stochastic Oscillator
- PBHC 68.29
- CLYM 0.00
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.